Degenerative Neurological Disorders Study Guide
Overview and Learning Objectives
Primary Objectives:
Identify the pathophysiologic processes responsible for various degenerative neurologic disorders.
Apply the nursing process as a structured framework for the care of patients diagnosed with degenerative neurologic disorders.
Myasthenia Gravis (MG)
Disease Definition and Pathophysiology:
Chronic autoimmune disorder affecting the neuromuscular junction (neuromotor junction).
Pathologically characterized by the production of immunoglobulin G (IgG) antibodies directed against acetylcholine receptors (AChRs).
Antibodies block nerve impulse transmission across the neuromuscular junction, lead to membrane damage, and reduce both the total number and availability of functional AChRs.
Results in muscle weakness and fatigue, particularly affecting ocular and cranial muscles.

Clinical Manifestations:
Ocular and Cranial Involvement: Muscle weakness predominantly affects the eyes (ptosis/drooping eyelids, diplopia/double vision), eyelids, chewing, swallowing (dysphagia), and speech (dysarthria, nasal quality to speech).
General Muscle Patterns: Proximal muscles of the neck, shoulder, and hips are involved; trunk and limb muscles are generally less affected.
Associated Neurological Findings: No loss of sensation occurs; deep tendon reflexes (DTRs) remain normal; muscle atrophy is rare.
Disease Course: Fluctuating course characterized by periods of exacerbations and remissions.
Respiratory Complications: Progressive weakness of respiratory muscles can lead to acute respiratory distress.
Diagnostic Evaluation:
Thorough history and physical examination.
Assay for autoantibodies against acetylcholine receptors (AChRs).
Upward gaze fatigue testing (sustained upward gaze causes progressive ptosis).
Electromyography (EMG) showing decremental response to repetitive nerve stimulation.
Tensilon Test: Intravenous administration of edrophonium chloride (), a short-acting anticholinesterase, which rapidly restores muscle strength temporarily in patients with MG.

Pharmacological & Surgical Management:
Anticholinesterase Medications: Pyridostigmine (Mestinon, ) and neostigmine (Prostigmin) inhibit acetylcholinesterase, increasing ACh concentration in the synaptic cleft.
Immunosuppressive Therapy: Corticosteroids (e.g., prednisone) to suppress antibody production.
Biologic Therapies: Currently under investigation in clinical trials for drug-resistant generalized MG.
Surgical Intervention: Thymectomy (surgical excision of the thymus gland) to eliminate a primary source of autoantibody production.

Plasmapheresis (Plasma Exchange):
Removes circulating acetylcholine receptor antibodies from the blood plasma.

Candidates for Plasmapheresis:
Severely disabled patients unresponsive to conventional therapies.
Patients experiencing myasthenic crisis.
Patients with respiratory impairment scheduled for surgical procedures.
Post-thymectomy patients exhibiting delayed remission.
Patients experiencing temporary clinical worsening during initiation of corticosteroid (prednisone) therapy.
Nursing Care & Swallow Function Screen:
Medication Administration: Administer anticholinesterase drugs precisely on schedule; coordinate peak drug effect with meal times to facilitate safer chewing and swallowing.
Respiratory Care: Maintain continuous respiratory assessment; ensure function suction equipment is always available at the bedside.
Activity & Energy Conservation: Plan activities early in the day when muscle strength is maximal; assess muscle strength prior to and following activities.
Swallow Function Protocol:
Arousal Level: Patient must demonstrate alertness without aggressive stimulation for at least continuous.
Oral Preparation: Patient must demonstrate unprompted lip seal/suck preparation with straw or cup sip.
Automatic Fail Criteria: If either arousal or oral preparation is negative, keep patient strict NPO and request Speech Language Pathology (SLP) evaluation.
Aspiration Risk Signs: Check for harsh/breathy voice, weak voluntary cough, impaired secretion management, or wet/gurgly vocal quality. Presence of ANY sign requires strict NPO status and SLP referral. If ALL signs are absent, supervised oral intake may begin using aspiration precautions (upright posture, small bites/sips, slow pace, no straws).
Comparison of Neuromuscular Crises:
Myasthenic Crisis:
Cause: Exacerbation of disease process or underdosage/omission of anticholinesterase medication.
Clinical Features: Severe generalized skeletal muscle weakness, ptosis, dysphagia, dysarthria, dyspnea.
Diagnostic Response: Muscle strength improves following administration of anticholinesterase medication.
Cholinergic Crisis:
Cause: Overdose of anticholinesterase medication leading to excessive accumulation of acetylcholine.
S/S Mnemonic (SLUDGE):
Salivation
Lacrimation
Urination
Defecation
Gastric upset
Emesis

Discharge Teaching:
Provide thorough instruction on the pathophysiology and progression of MG.
Emphasize strict adherence to the medication regimen; schedule meals to coincide with peak drug activity.
Train patient and family in operating home suction equipment.
Teach differentiation between signs of medication underdose (myasthenic crisis) and overdose (cholinergic crisis).
Educate on precipitating factors (infection, fever, emotional stress, extreme temperatures).
Recommend soft/semisolid dietary textures to lower aspiration risks.
Coordinate referrals for occupational therapy (OT), home health care, adaptive eating equipment, and community support groups.
Amyotrophic Lateral Sclerosis (ALS)
Disease Overview:
Commonly designated as Lou Gehrig's disease.
Etiology remains unknown.
Fatal neurodegenerative disease leading to death within to post-diagnosis, primarily due to respiratory failure.
Pathophysiology:
Progressive degeneration and demyelination of motor neurons situated in the anterior horn of the spinal cord, brainstem, and cerebral cortex.
Involves both upper motor neurons (UMN) and lower motor neurons (LMN).
Interrupts electrical and chemical signal transmission from the brain to skeletal muscles.
Compensatory reinnervation occurs early in the disease process but ultimately fails as motor neuron loss progresses.

Epidemiology and Clinical Features:
Peak onset occurs between and of age.
Higher incidence in males at younger ages; equal incidence between genders post-menopause.
Characterized by progressive muscle weakness and wasting without impairment of sensory or cognitive functions.
Early Findings: Muscle spasticity and hyperreflexia (UMN signs) alongside muscle flaccidity, paresis, atrophy, and fasciculations (LMN signs).
Distribution: Muscle weakness usually originates in distal upper extremities (hands, shoulders, arms) before advancing to lower extremities.
Cranial Nerve Involvement: Atrophy of facial and tongue muscles produces severe dysphagia and dysarthria.
Systemic Complications: Inability to manage oral secretions, emotional lability (uncontrollable laughter or crying), and respiratory muscle exhaustion.
Diagnostic Workup:
Diagnosis is clinical, requiring rule-out of mimicking disorders (hyperthyroidism, spinal cord compression, neuroinfections, central nervous system neoplasms).
Electromyography (EMG): Differentiates neuropathic changes from primary myopathy.
Muscle Biopsy: Demonstrates denervation atrophy and loss of muscle fibers.
Serum Creatine Kinase (CK): Non-specifically elevated.
Pulmonary Function Tests (PFTs): Quantifies degree of respiratory muscle compromise.
Medical & Experimental Management:
Rilutek (Riluzole): Antiglutamate agent prescribed to inhibit glutamate release and slow motor neuron degradation.
Mandatory laboratory monitoring: Liver function tests (LFTs), complete blood count (CBC), serum chemistries, alkaline phosphatase.

Experimental Immunotherapy (Treg Protocol):
Involves leukapheresis to isolate patient T-regulatory lymphocytes (Tregs), which are expanded ex vivo.
Administered alongside concomitant interleukin-2 ().
Dosage regimen: Early-stage disease receives over ; late-stage disease receives over .
Trial outcomes demonstrated significant slowing of disease progression rates across both early and late stages.
Interdisciplinary Nursing Care:
Focus on preventing complications associated with severe immobility (pressure injuries, venous thromboembolism, atelectasis).
Guide patient and family through early advance care planning regarding gastrostomy tube placement, invasive/non-invasive mechanical ventilation, and augmentative communication systems.
Guillain-Barré Syndrome (GBS)
Pathophysiology:
Acute inflammatory demyelinating polyneuropathy (AIDP).
Etiology is autoimmune, frequently triggered by an antecedent infection (respiratory or gastrointestinal, such as Campylobacter jejuni enteritis) or historically linked to specific vaccinations.
Humoral and cell-mediated immune responses (IgG antibodies, complement activation, and macrophage invasion) destroy the myelin sheath surrounding peripheral nerve axons.

Clinical Manifestations:
Rapid onset of progressive, symmetrical, ascending flaccid paralysis affecting extremities.
Accompanied by sensory disturbances (paresthesias, numbness) starting in the feet/hands.
Reflexes: Marked hyporeflexia or complete areflexia.
Autonomic Nervous System Dysfunction: Blood pressure volatility (severe hypertension/hypotension), cardiac dysrhythmias, paralytic ileus, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), and urinary retention.
Systemic Findings: Initial absence of fever; cranial nerve deficits (facial diplegia, extraocular movement weakness).
Timeline: Progression evolves over days to several weeks; recovery typically initiates to following stabilization of symptom progression.

Diagnostic Evaluation:
Detailed clinical evaluation and patient history.
Cerebrospinal Fluid (CSF) Analysis: Elevated protein levels without elevation in white blood cell count (albuminocytological dissociation).
Electromyography (EMG) / Nerve Conduction Studies: Shows slowed nerve conduction velocity.
Pulmonary Function Tests: Vital capacity and negative inspiratory force measurements determine respiratory compromise.
Medical & Interdisciplinary Management:
Emergency Care: Life-threatening medical emergency due to impending acute neuromuscular respiratory failure.
Disease-Modifying Therapies:
Plasmapheresis (Plasma Exchange): Effective when initiated within of symptom onset; typically administered to across a to window.
Intravenous Immunoglobulin (IVIG): Equal efficacy to plasmapheresis in neutralizing autoantibodies.
Surgical Support: Tracheostomy placement for patients requiring extended mechanical ventilation.
Pharmacotherapy: Prophylactic antibiotics, morphine for severe neuropathic pain, anticoagulation (low-molecular-weight heparin) for VTE prophylaxis, vasopressors for autonomic hypotension.
Nutritional & Physical Support: Enteral tube feeding or Total Parenteral Nutrition (TPN); early physical and occupational therapy for long-term functional recovery.
Nursing Care:
Continuous respiratory monitoring and airway maintenance.
Continuous electrocardiogram (ECG) monitoring for dysrhythmias; monitor fluid volume status and treat hypotension with IV fluids.
Implement deep vein thrombosis (DVT) prevention strategies (sequential compression devices, passive range of motion).
Provide communication boards and emotional reassurance to reduce acute anxiety.
Multiple Sclerosis (MS)
Disease Profile:
Chronic, progressive, degenerative autoimmune disorder of the central nervous system (CNS).
Characterized by disseminated demyelination of nerve fibers in the brain and spinal cord, followed by gliosis (scar tissue scarring).
Typical age of onset is between and of age; higher prevalence in females than males; displays familial predisposition.
Pathophysiology:
Triggered by viral exposure in genetically susceptible individuals.
An antigen-antibody reaction initiates inflammatory destruction of myelin sheaths surrounding axons.
Early Stage: Axons remain intact despite myelin degradation; myelin regeneration is possible, producing complete or partial symptom remission.
Late Stage: Recurrent neuroinflammation destroys underlying axons, causing permanent nerve deficit and plaque formation (sclerosis) throughout the CNS.

Clinical Patterns & Manifestations:
Disease trajectories include relapsing-remitting patterns or chronic, progressive functional decline.
Motor Manifestations: Limb, trunk, or facial weakness/paralysis, muscle spasticity, diplopia, scanning speech.
Sensory Manifestations: Paresthesias (numbness and tingling), blurred vision, vertigo, tinnitus, decreased hearing acuity, chronic neuropathic pain.
Pseudobulbar Affect (PBA): Involuntary, sudden, uncontrollable, and context-inappropriate laughing or crying outbursts.
Cerebellar Signs: Nystagmus (involuntary ocular oscillations), cerebellar ataxia, dysarthria, dysphagia.
Neuropsychiatric Manifestations: Severe fatigue, deep depression, emotional anger outbursts.
Bowel & Bladder Dysfunction:
Constipation: Secondary to immobility or neurogenic bowel impairment.
Spastic (Uninhibited) Bladder: Small bladder capacity causing urinary frequency, urgency, and urge incontinence.
Flaccid (Hypotonic) Bladder: Abnormally large capacity with absent sensation of fullness, causing urinary retention and overflow overflow.
Diagnostic Workup:
No single pathognomonic diagnostic test.
Diagnosis relies on thorough history, clinical presentation, and exclusion of alternative diagnoses.
Magnetic Resonance Imaging (MRI): Visualizes multifocal sclerotic plaques across brain and spinal cord white matter.

Collaborative Therapies:
Biologic Therapy: Ocrevus (ocrelizumab), a humanized monoclonal antibody targeting CD20-positive B-lymphocytes responsible for axonal damage and demyelination (approximate cost: ).
Physical Therapy: Focused on reducing spasticity, optimizing motor coordination, and training compensation using unaffected muscle groups.
Nutritional Support: High-protein, high-fiber diet supplemented with megavitamins; low-fat, gluten-free, and raw vegetable diets are frequently utilized.
Nursing Interventions:
Assist in identifying individual symptom triggers (infections, fever, physical fatigue, stress, hot/cold temperature extremes) and developing avoidance strategies.
Educate on balancing rest and physical exercise; emphasize infection prevention.
Teach clean self-catheterization protocols for patients with flaccid bladder retention.
Recommend elevated dietary fiber and adequate hydration to maintain regular bowel function.
Parkinson's Disease (PD)
Disease Overview:
Chronic, progressive neurodegenerative disorder severely impairing motor control.
Typical age of onset is approximately (gradual onset usually after age ).
Rare in individuals under ; to of cases present before age ; low incidence in Black populations.
Pathophysiology:
Progressive destruction of dopaminergic neurons in the substantia nigra of the basal ganglia.
Causes severe depletion of striatal dopamine stores and degeneration of the dopaminergic nigrostriatal pathway.
Results in a critical neurochemical imbalance: deficient inhibitory dopamine (DA) relative to excessive excitatory acetylcholine (ACh) in the corpus striatum.
Disruption of extrapyramidal pathways impairs complex voluntary movement execution. Microscopic examination demonstrates intracellular Lewy bodies.

Cardina Motor Triad & Clinical Features:
Tremor: Resting tremor displaying a characteristic "pill-rolling" finger movement; worsens with emotional stress; may involve jaw, tongue, lips, and diaphragm.
Rigidity: Increased resistance to passive limb movement, exhibiting